DPM-1003 / DepYmed - LARVOL DELTA

DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome (GlobeNewswire) - "...DepYmed announces it has received clearance from the U.S. Food and Drug Administration to initiate its phase 1 clinical trial for DPM-1003 for the treatment of Rett Syndrome....'We look forward to beginning to assess the safety and tolerability of DPM-1003 and continue our development of this compound for Rett Syndrome and our other ongoing programs.'"

New P1 trial • CNS Disorders • Developmental Disorders

DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting (GlobeNewswire) - "DepYmed, Inc...announces the presentation of a development update for its small molecule PTP1B inhibitor program and its lead clinical candidate, DPM-1003, at the 2023 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting. The Company presented a poster outlining the development of DPM-1003 and Dr. Nicholas Tonks, DepYmed’s founding scientist, delivered a podium presentation demonstrating the potential of this new treatment of Rett Syndrome. The conference was held June 5-7, 2023 at the Nashville Marriott at Vanderbilt University in Nashville, Tenn. The data illustrated the Company’s mechanism-based approach and provided an overview of DPM-1003 preclinical efficacy and safety moving the compound through IND-enabling studies to initiate clinical studies in 2024. The data demonstrate that DPM-1003 is a potent, specific inhibitor of PTP1B and a potential once-daily orally administered drug to treat Rett Syndrome."

New trial • Preclinical • CNS Disorders • Developmental Disorders

DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting (GlobeNewswire) - "Today DepYmed announces it will be presenting two abstracts on its small molecule PTP1B inhibitor program at the 2023 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting. The conference will be held June 5-7, 2023 at the Nashville Marriott at Vanderbilt University in Nashville, Tenn."

Preclinical • Developmental Disorders